Navigation Links
ADVENTRX Exploring Strategic Options
Date:12/15/2008

SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of cancer, today announced that it is exploring a range of strategic options, including the sale or disposition of one or more of its product candidate programs, a strategic business merger and other transactions that maximize the value of Company's assets. The Company is currently in discussions with several candidates for both strategic and partnering transactions.

"Publicly announcing our exploration of strategic alternatives provides the best opportunity to find a partner who wishes to acquire one or both of our late-stage oncology assets," stated Mark Bagnall, the Company's Executive Vice President and Chief Financial Officer. "As we expand our horizons, we continue both our on-going discussions with potential pharmaceutical partners and to conduct those activities that maintain the value of our lead programs. We believe that ADVENTRX offers its partners near-term up-side in an otherwise tumultuous market and has the potential to deliver attractive returns by way of its innovative lower-cost, lower-risk business model."

ADVENTRX currently is focused on commercializing two late-stage product candidates in the U.S., both of which are reformulations of currently approved products and are designed to improve the safety profile of the approved product without affecting its efficacy. ANX-514 (docetaxel emulsion) is a reformulation of the blockbuster chemotherapeutic agent, Taxotere(R). In 2007, the aggregate worldwide market for Taxotere was in excess of $3 billion. ANX-530 (vinorelbine emulsion) is a reformulation of Navelbine(R) which, despite being a generic product for a number of years, still
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. ADVENTRX Announces Consolidation of Clinical and Management Positions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... MENLO PARK, Calif. , Feb. 26, 2015 /PRNewswire/ ... has released the latest version of the Governance ... organizations accomplish governance, risk and compliance (GRC) tasks across ... has also been updated to help customers better align ... Organizations of the Treadway Commission ) requirements. In response ...
(Date:2/26/2015)... Angeles, CA (PRWEB) February 26, 2015 ... an online demonstration to support life extension technologies and ... 8pm UTC, Universal Coordinated Time, on March 21st 2015, ... the world. , Eric Schulke, Founder of MILE, ... must act with urgency. The Movement for Indefinite Life ...
(Date:2/26/2015)...  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the ... hair rejuvenation, has announced that it has selected ... investor relations and strategic communications. ... diversification strategies – and we need to communicate ... Ali Kharazmi CEO of NuGene when announcing this ...
(Date:2/26/2015)... , Feb. 26, 2015 BioEnterprise today ... companies have attracted more than $2 billion in growth ... local and national investors, strategic sources, state – including ... half of the $2 billion has been raised in ... comes on the heels of the BioEnterprise Midwest ...
Breaking Biology Technology:Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4
... international research team has developed a mathematical and cartographical model ... in the aftermath of forest fires. In order to carry ... Environmental Modelling & Software , the authors studied a Special ... "We have developed a model that shows on maps ...
... SAN CARLOS, Calif., July 31 Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2009 on Tuesday, August 4, 2009, ... chief executive officer, will host a conference call to review the ... (PT). , , The press release and ...
... ANNAPOLIS, Md., July 31 PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, today announced that, effective July 28, ... unsecured senior convertible notes ("Notes") and common stock purchase warrants ... , In connection with the private placement, ...
Cached Biology Technology:Model predicts evolution of Mediterranean landscape following fires 2Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets 2PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , a ... today announced that Murali Prahalad , Ph.D., president and ... World Conference (PMWC) 2015: Silicon Valley, which is taking ... View, Calif. on January 26-28, 2015. ... of Age as Biomarkers." Last year, Epic Sciences was a ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... MBL, WOODS HOLE, MA-- Squid,s colorful, changeable skin ... octopus--to display extraordinary camouflage, the speed and diversity ... But how squid control their skin,s iridescence, ... animal,s sparkly rainbow of color, has been unknown. ...
... , This release is available in German ... three dimensional objects on a micrometer scale. But how can ... precision? Scientists at the Vienna University of Technology developed ... When biological tissue is grown, this method can allow the ...
... at the California Institute of Technology (Caltech) have made ... of individual molecules one at a time. ... doctors diagnose diseases, enable biologists to study viruses and ... scientists to better measure nanoparticles and air pollution. ...
Cached Biology News:MBL scientists discover nerves control iridescence in squid’s remarkable 'electric skin' 2The laser beam as a '3-D painter' 2Weighing molecules 1 at a time 2Weighing molecules 1 at a time 3Weighing molecules 1 at a time 4
... For nucleofection of optimized cell lines in ... the nucleofection parameters. Nucleofector Kits are only ... Different cell lines can be transfected with ... are given in brackets in percent (Efficiency ...
... Human Pathogenic Viruses The National ... preserves well characterised, authenticated human ... facility, and NCPV is able ... nucleic acids derived from them, ...
B-FABP (FL-132)...
... a highly purified preparation of the catalytic ... which recognizes the identical cleavage site as ... enzymatic activity (1). Novagen&'s enzyme is produced ... the highest activity available, and is qualified ...
Biology Products: